Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation

Remdesivir is the first FDA-approved drug for treating severe SARS-CoV-2 infection and targets RNA-dependent RNA polymerase (RdRp) that is required for viral replication. To monitor for the development of mutations that may result in remdesivir resistance during prolonged treatment, we sequenced SAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shangxin, Multani, Ashrit, Garrigues, Jacob M., Oh, Michael S., Hemarajata, Peera, Burleson, Taylor, Green, Nicole M., Oliai, Caspian, Gaynor, Pryce T., Beaird, Omer E., Winston, Drew J., Seet, Christopher S., Schaenman, Joanna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460003/
https://www.ncbi.nlm.nih.gov/pubmed/37630656
http://dx.doi.org/10.3390/microorganisms11082096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460003/
https://www.ncbi.nlm.nih.gov/pubmed/37630656
http://dx.doi.org/10.3390/microorganisms11082096

Ejemplares similares